Allogene Therapeutics Inc (ALLO)

03:52 AM

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

03:52 AM

May 16, 2025

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

May 16, 2025

May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025

May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025

May 15, 2025

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus

May 15, 2025

May 15, 2025

ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus

May 15, 2025

May 15, 2025

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 15, 2025

May 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timeline Delays | ALLO Stock News - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Truist Secu - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Stock Drops Amid Trial Delays - GuruFocus

May 14, 2025

May 14, 2025

RBC Capital Reiterates Outperform Rating for Allogene Therapeuti - GuruFocus

May 14, 2025

May 14, 2025

Piper Sandler Lowers Price Target for Allogene Therapeutics (ALL - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics stock falls on trial delay, downgrade - Seeking Alpha

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO): Price Target Lowered by Analyst | - GuruFocus

May 14, 2025

May 14, 2025

Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating - marketscreener.com

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Downgraded by Citizens JMP | ALLO S - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer | ALLO Stock News - GuruFocus

May 14, 2025

May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025

May 14, 2025

Allogene (ALLO) Pioneers Future of Cell Therapy with Innovative Strategies | ALLO Stock News - GuruFocus

May 14, 2025

May 14, 2025

Truist Lowers Price Target for Allogene Therapeutics (ALLO) Amid Trial Delays | ALLO Stock News - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Target Price Adjusted by Oppenheimer | ALLO Stock News - GuruFocus

May 14, 2025

May 14, 2025

Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating - marketscreener.com

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Sees Price Target Reduction by Anal - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer - TipRanks

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Price Target Reduced Amid Trial Del - GuruFocus

May 14, 2025

May 14, 2025

Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com

May 14, 2025

May 14, 2025

Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential - TipRanks

May 14, 2025

May 14, 2025

Allogene downgraded to Market Perform from Outperform at Citizens JMP - TipRanks

May 14, 2025

May 14, 2025

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 14, 2025

May 14, 2025

Allogene Therapeutics (ALLO) Sees Strategic Delays and Financial Optimizations - GuruFocus

May 14, 2025

May 14, 2025

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Operational Challenges - GuruFocus

May 14, 2025

May 13, 2025

Allogene Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 13, 2025

May 13, 2025

Earnings call transcript: Allogene Therapeutics reports Q1 2025 loss By Investing.com - Investing.com Nigeria

May 13, 2025

May 13, 2025

Earnings call transcript: Allogene Therapeutics reports Q1 2025 loss - Investing.com Australia

May 13, 2025

May 13, 2025

Allogene Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

May 13, 2025

Allogene Therapeutics Inc QTRLY Loss Per Share $0.28 - marketscreener.com

May 13, 2025

May 13, 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - The Manila Times

May 13, 2025

May 13, 2025

Allogene Earnings Update: Clinical Trials Advance as Cash Runway Extends to 2027, ASCO Data Coming - Stock Titan

May 13, 2025

May 13, 2025

Transcript : Allogene Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com

May 13, 2025

May 13, 2025

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus

May 13, 2025

May 10, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - MSN

May 10, 2025

May 09, 2025

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025